Literature DB >> 1795043

In vitro interleukin-1 (IL-1) production in thymic hyperplasia and thymoma from patients with myasthenia gravis.

C Aime1, S Cohen-Kaminsky, S Berrih-Aknin.   

Abstract

Using a biological test, we measured in vitro thymic epithelial cell IL-1 activity of 14 thymomas and 8 hyperplasia from myasthenic patients. Our results demonstrate that thymic epithelial cells from hyperplastic thymuses spontaneously produce high amounts of IL-1 compared to controls, while cells from thymomas produce very low amounts of IL-1. After LPS stimulation the difference between patients and controls is no longer significant. Immunohistochemistry studies demonstrate a limited number of IL-1-positive cells on sections from normal thymuses and a variable number of IL-1-positive cells on diseased thymuses, not clearly correlated to the in vitro production. In hyperplastic thymuses an association is found between the level of hyperplasia and in vitro IL-1 production, suggesting a role for IL-1 in the expansion of thymic lymphoid follicles. In thymoma, the low IL-1 production and the loss of corticomedullary organisation raise the possibility that some autoreactive clones could emerge from the lymphocyte pool, present in the abnormal tumoral microenvironment.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1795043     DOI: 10.1007/BF00918185

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  51 in total

1.  Antibodies to Epstein-Barr virus in 50 patients with thymic tumor.

Authors:  C Perronne; T Ooka; G Decaussin; G De Thé; S Berrih-Aknin; J M Verley
Journal:  JAMA       Date:  1990-08-01       Impact factor: 56.272

2.  IL-6 is an intermediate in IL-1-induced thymocyte proliferation.

Authors:  M Helle; L Boeije; L A Aarden
Journal:  J Immunol       Date:  1989-06-15       Impact factor: 5.422

3.  Evidence of enhanced recombinant interleukin-2 sensitivity in thymic lymphocytes from patients with myasthenia gravis: possible role in autoimmune pathogenesis.

Authors:  S Cohen-Kaminsky; P Levasseur; J P Binet; S Berrih-Aknin
Journal:  J Neuroimmunol       Date:  1989-09       Impact factor: 3.478

Review 4.  The interleukins in acquired disease.

Authors:  M Malkovský; P M Sondel; W Strober; A G Dalgleish
Journal:  Clin Exp Immunol       Date:  1988-11       Impact factor: 4.330

5.  Interleukin 1 and T-cell activation.

Authors:  S B Mizel
Journal:  Immunol Today       Date:  1987

6.  Distinct roles of IL-1 and IL-6 in human T cell activation.

Authors:  F A Houssiau; P G Coulie; J Van Snick
Journal:  J Immunol       Date:  1989-10-15       Impact factor: 5.422

7.  Clinical, pathological, HLA antigen and immunological evidence for disease heterogeneity in myasthenia gravis.

Authors:  D A Compston; A Vincent; J Newsom-Davis; J R Batchelor
Journal:  Brain       Date:  1980-09       Impact factor: 13.501

8.  [Surgical treatment of myasthenia by thymectomy. A report on 248 cases (author's transl)].

Authors:  H Le Brigand; P Levasseur; A R Miranda; C Gaud; I Wojakowski
Journal:  Ann Chir       Date:  1980-03

9.  Purification, cloning, expression and biological characterization of an interleukin-1 receptor antagonist protein.

Authors:  D B Carter; M R Deibel; C J Dunn; C S Tomich; A L Laborde; J L Slightom; A E Berger; M J Bienkowski; F F Sun; R N McEwan
Journal:  Nature       Date:  1990-04-12       Impact factor: 49.962

10.  Thymoma. A comparative study of clinical stages, histologic features, and survival in 200 cases.

Authors:  J M Verley; K H Hollmann
Journal:  Cancer       Date:  1985-03-01       Impact factor: 6.860

View more
  4 in total

Review 1.  Thymic Germinal Centers and Corticosteroids in Myasthenia Gravis: an Immunopathological Study in 1035 Cases and a Critical Review.

Authors:  Frédérique Truffault; Vincent de Montpreville; Bruno Eymard; Tarek Sharshar; Rozen Le Panse; Sonia Berrih-Aknin
Journal:  Clin Rev Allergy Immunol       Date:  2017-02       Impact factor: 8.667

2.  Characterization of CD4 and CD8 T cell responses in MuSK myasthenia gravis.

Authors:  J S Yi; A Guidon; S Sparks; R Osborne; V C Juel; J M Massey; D B Sanders; K J Weinhold; J T Guptill
Journal:  J Autoimmun       Date:  2013-12-28       Impact factor: 7.094

3.  Comparative Analysis of Thymic and Blood Treg in Myasthenia Gravis: Thymic Epithelial Cells Contribute to Thymic Immunoregulatory Defects.

Authors:  Frédérique Truffault; Dani Nazzal; Julien Verdier; Angeline Gradolatto; Elie Fadel; Régine Roussin; Bruno Eymard; Rozen Le Panse; Sonia Berrih-Aknin
Journal:  Front Immunol       Date:  2020-05-06       Impact factor: 7.561

Review 4.  Myasthenia Gravis: An Acquired Interferonopathy?

Authors:  Cloé A Payet; Axel You; Odessa-Maud Fayet; Nadine Dragin; Sonia Berrih-Aknin; Rozen Le Panse
Journal:  Cells       Date:  2022-04-04       Impact factor: 6.600

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.